Show simple item record

dc.contributor.authorMohr, E
dc.contributor.authorDaniels, J
dc.contributor.authorBeko, B
dc.contributor.authorIsaakidis, P
dc.contributor.authorCox, V
dc.contributor.authorSteele, S
dc.contributor.authorMuller, O
dc.contributor.authorSnyman, L
dc.contributor.authorDe Azevedo, V
dc.contributor.authorShroufi, A
dc.contributor.authorTrivino Duran, L
dc.contributor.authorHughes, J
dc.date.accessioned2017-06-04T16:10:46Z
dc.date.available2017-06-04T16:10:46Z
dc.date.issued2017-05-18
dc.date.submitted2017-05-30
dc.identifier.citationDOT or SAT for Rifampicin-Resistant Tuberculosis? A Non-Randomized Comparison in a High HIV-Prevalence Setting. 2017, 12 (5):e0178054 PLoS ONEen
dc.identifier.issn1932-6203
dc.identifier.pmid28542441
dc.identifier.doi10.1371/journal.pone.0178054
dc.identifier.urihttp://hdl.handle.net/10144/618932
dc.description.abstractDaily directly-observed therapy (DOT) is recommended for rifampicin-resistant tuberculosis (RR-TB) patients throughout treatment. We assessed the impact of self-administered treatment (SAT) in a South African township with high rates of RR-TB and HIV.
dc.language.isoenen
dc.publisherPublic Library of Scienceen
dc.rightsPublished by Public Library of Science, [url]http://www.plosone.org/[/url] Archived on this site by Open Access permissionen
dc.titleDOT or SAT for Rifampicin-Resistant Tuberculosis? A Non-Randomized Comparison in a High HIV-Prevalence Settingen
dc.identifier.journalPLoS ONEen
refterms.dateFOA2019-03-04T13:24:24Z
html.description.abstractDaily directly-observed therapy (DOT) is recommended for rifampicin-resistant tuberculosis (RR-TB) patients throughout treatment. We assessed the impact of self-administered treatment (SAT) in a South African township with high rates of RR-TB and HIV.


Files in this item

Thumbnail
Name:
Mohr et al - 2017 - DOT or SAT ...
Size:
2.078Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record